4 / 18
CA-209-003: Nivolumab
Probability of Survival
Months
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0
12
24
36
48
60
72
84
6
18
30
42
54
66
78
Database lock Oct 2015
107
64
86
51
49
41
29
0
3
15
43
36
17
12
1
Number of Patients at Risk
All Patients
All Patients (events: 69/107), median and 95% CI: 17.3 (12.5
–
37.8)
NIVO 3 mg/kg (events: 11/17), median and 95% CI: 20.3 (7.2
–
NR)
17
11
15
9
8
7
6
1
6
7
6
6
6
0
NIVO 3 mg/kg
OS Rate, % (95% CI)*
Landmark timepoint
All Patients
(N = 107)
NIVO 3 mg/kg
(n = 17)
12-month
63 (53
–
71)
65 (38
–
82)
24-month
48 (38
–
57)
47 (23
–
68)
36-month
42 (32
–
51)
41 (19
–
63)
48-month
35 (26
–
44)
35 (15
–
57)
60-month
34 (25
–
43)
35 (15
–
57)
Median OS, onths (95% CI)
17.3 (12.5
–
37.8)
20.3 (7.2-NR)
Hodi FS. AACR 2016 Abstract CT001